Literature DB >> 21801593

Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes.

Weiguo Li1, Kamakshi Sachidanandam, Adviye Ergul.   

Abstract

OBJECTIVES: Cerebrovascular tone plays a key role in controlling cerebral blood flow. Our studies have demonstrated that the endothelin system is upregulated in type 2 diabetes leading to increased sensitivity to endothelin-1 and decreased relaxation in basilar artery. While chronic endothelin A receptor blockade restored relaxation, selective endothelin B receptor blockade caused paradoxical constriction in diabetes. Whether this effect was due to activation of endothelin A receptors in the presence of endothelin B receptor blockade or due to the loss of vasculoprotective effects of endothelin B receptors remained unknown. The current study hypothesizes that due to the antagonism of the vasculoprotective endothelin receptor B, dual blockade will not be as effective as selective endothelin receptor A antagonism in improving cerebrovascular dysfunction in type 2 diabetes.
METHODS: These studies were done in non-obese, type 2 diabetic Goto-Kakizaki rats administered either vehicle, selective endothelin receptor A antagonist Atrasentan (5 mg/kg) or dual endothelin antagonist Bosentan (100 mg/kg) for 4 weeks. At termination, basilar arteries were collected and mounted on a wire myograph and cumulative dose-response curves to endothelin-1 (1-500 nM) and acetylcholine (1 nM-5 μm) were studied.
RESULTS: Basilar artery was highly sensitive to endothelin-1-mediated constriction in diabetic animals. While neither Atrasentan nor Bosentan affected endothelium-dependent vascular relaxation in control animals, both treatments improved the maximum dilatation in diabetes and Atrasentan also improved sensitivity to acetylcholine.
CONCLUSION: In light of our previous data which showed that endothelin B receptors are vasculoprotective and blockade of this receptor worsens relaxation, current findings suggest that when blocked simultaneously with the endothelin receptor A, the endothelin receptor B antagonism is protective by reducing the hyperreactivity and improving cerebrovascular function in diabetes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21801593      PMCID: PMC3725271          DOI: 10.1179/016164111X12881719352417

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  49 in total

1.  Stimulation of insulin release in hereditarily diabetic rats by mixed molecules formed of nateglinide and a succinic acid ester.

Authors:  L Ladriere; F Bjorkling; W J Malaisse
Journal:  Int J Mol Med       Date:  2000-01       Impact factor: 4.101

2.  Does blockade of endothelinB1-receptor activation increase endothelinB2/endothelinA receptor-mediated constriction in the rabbit basilar artery?

Authors:  M Zuccarello; R Boccaletti; R M Rapoport
Journal:  J Cardiovasc Pharmacol       Date:  1999-05       Impact factor: 3.105

Review 3.  Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction.

Authors:  G M Pieper
Journal:  Hypertension       Date:  1998-05       Impact factor: 10.190

Review 4.  Hyperglycemia and cardiovascular disease in type 2 diabetes.

Authors:  M Laakso
Journal:  Diabetes       Date:  1999-05       Impact factor: 9.461

5.  Increased expression of endothelin B receptors in the diabetic rabbit urinary bladder: functional relevance.

Authors:  F H Mumtaz; M R Dashwood; C S Thompson; M E Sullivan; D P Mikhailidis; R J Morgan
Journal:  BJU Int       Date:  1999-01       Impact factor: 5.588

6.  Nonfasting serum glucose and insulin concentrations and the risk of stroke.

Authors:  S G Wannamethee; I J Perry; A G Shaper
Journal:  Stroke       Date:  1999-09       Impact factor: 7.914

7.  Impairment of endothelium-dependent relaxation of the isolated basilar artery from streptozotocin-induced diabetic rats.

Authors:  K Kamata; H Kondoh
Journal:  Res Commun Mol Pathol Pharmacol       Date:  1996-12

8.  Constrictor responses of the rat basilar artery during diabetes mellitus.

Authors:  W G Mayhan
Journal:  Brain Res       Date:  1998-02-09       Impact factor: 3.252

9.  Increased contractile responses to endothelin-1 and U46619 via a protein kinase C-mediated nifedipine-sensitive pathway in diabetic rat aorta.

Authors:  Y Hattori; H Kawasaki; M Kanno
Journal:  Res Commun Mol Pathol Pharmacol       Date:  1999

10.  The effects of endothelin-1 and NG-nitro-L-arginine methyl ester on regional haemodynamics in conscious rats with streptozotocin-induced diabetes mellitus.

Authors:  R J Kiff; S M Gardiner; A M Compton; T Bennett
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

View more
  5 in total

1.  Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control.

Authors:  Mohammed Abdelsaid; Jessica Kaczmarek; Maha Coucha; Adviye Ergul
Journal:  Life Sci       Date:  2014-01-18       Impact factor: 5.037

2.  Linagliptin reduces effects of ET-1 and TLR2-mediated cerebrovascular hyperreactivity in diabetes.

Authors:  Trevor Hardigan; Yasir Abdul; Adviye Ergul
Journal:  Life Sci       Date:  2016-02-17       Impact factor: 5.037

3.  Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes.

Authors:  Mohammed Abdelsaid; Handong Ma; Maha Coucha; Adviye Ergul
Journal:  Life Sci       Date:  2014-01-13       Impact factor: 5.037

4.  Early effects of high-fat diet on neurovascular function and focal ischemic brain injury.

Authors:  Weiguo Li; Roshini Prakash; Dhruv Chawla; Wenting Du; Sean P Didion; Jessica A Filosa; Quanguang Zhang; Darrell W Brann; Victor V Lima; Rita C Tostes; Adviye Ergul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-10       Impact factor: 3.619

Review 5.  The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis.

Authors:  Agata Kowalczyk; Paulina Kleniewska; Michal Kolodziejczyk; Beata Skibska; Anna Goraca
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-10-07       Impact factor: 4.291

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.